Return of the megarounds; Nvidia’s AI pitch to biotech; Bayer’s shakeup reaches the top; AstraZeneca buys into radiopharma; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In case you missed it, we launched our lat­est newslet­ter this week. Post-Hoc, as we call it, is a week­ly(ish) piece of analy­sis that fol­lows big news, an in­sight from the jour­nal­ist who broke the sto­ry, or a per­spec­tive that’s cru­cial to un­der­stand­ing events shap­ing bio­phar­ma and health­care. Learn more and sign up for it here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.